Acrylamide and Health Outcomes
Launched by KAROLINSKA INSTITUTET · Jan 16, 2024
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial, titled "Acrylamide and Health Outcomes," is studying the potential health risks associated with acrylamide, a chemical that can form in foods during cooking and processing. Researchers want to find out if higher levels of acrylamide in the blood are linked to serious health issues like dementia, Alzheimer's disease, Parkinson's disease, and heart attacks. They will collect blood samples from around 2,145 participants over the course of 20 years to analyze the relationship between acrylamide exposure and these health conditions.
To participate in this study, you need to be an adult aged 18 or older and have your blood measured during the recruitment phase. However, if you currently have any of the diseases being studied, you won't be eligible to join. By participating, you will help researchers gather important information that could lead to safer food practices and better nutrition, which may ultimately reduce the risk of these diseases in the general population. The study will run from 2024 to 2028, and the findings could help shape public health recommendations in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults (18 years old)
- • blood measured at the recruitment
- Exclusion Criteria:
- • prevalent cases of the diseases investigated
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Federica Laguzzi
Principal Investigator
Karolinska Instittutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported